Weak immunogenicity of the preS2 sequence and lack of circumventing effect on the unresponsiveness to the hepatitis B virus vaccine

Vaccine

Volumn 13, Issue 3, 1995, Pages 289-294

  Pillot, J ^a,c   Poynard, T ^a   Elias, A ^b   Maillard, J ^a   Lazizi, Y ^a   Brancer, M ^b   Dubreuil, P ^a   Budkowska, A ^c   Chaput, J C ^a  

^a HÔPITAL ANTOINE BÉCLÈRE   (France)

^b BICHAT HOSPITAL   (France)

^c INSTITUT PASTEUR   (France)

Author keywords

hepatitis B; Immunogenicity; preS2 sequence

Indexed keywords

HEPATITIS B VACCINE;

ADULT; ALCOHOL CONSUMPTION; ANTIBODY PRODUCTION; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; HEPATITIS B; HUMAN; HUMAN EXPERIMENT; MALE; NORMAL HUMAN; PRIORITY JOURNAL; RADIOIMMUNOASSAY; VACCINATION;

ADULT; ALCOHOL DRINKING; ANTIBODIES, VIRAL; HEPATITIS B ANTIBODIES; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B VACCINES; HUMANS; PROTEIN PRECURSORS; SENSITIVITY AND SPECIFICITY; VACCINES, SYNTHETIC; VIRAL ENVELOPE PROTEINS;

EID: 0028914040     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/0264-410X(95)93316-2     Document Type: Article

References (43)

1. Progress in hepatitis B immunization
2. Hepatitis B vaccine in the expanded programme of immunization the Gambia experience
3. Antibody responses of adults, adolescents, and children to a plasma-derived hepatitis B vaccine in a rural African setting
4. Recombinant yeast derived hepatitis B vaccine in healthy adults: safety and two year immunogenicity of early investigative lots of vaccine
5. Prevention of hepatitis B transmission at birth
6. Hepatitis B vaccine in the prevention of perinatally transmitted hepatitis B virus infection: final report on a West Midlands pilot study
7. Active immunization of homosexual men using a recombinant hepatitis B vaccine
8. Randomised placebo-controlled trial of hepatitis B surface antigen in French hemodialysis units. II. Hemodialysis patients
9. Reduced immunogenicity of hepatitis B vaccine in patients with chronic non A non B (type C)
10. Hepatitis B vaccination in chronic alcoholics
11. Hepatitis B vaccination Response of alcoholic with and without liver injury
12. Immune response to hepatitis B vaccine in parenteral drug abusers
13. Genetic prediction of nonresponse to hepatitis B vaccine
14. Genetic control of nonresponsiveness to hepatitis B virus vaccine by an extended HLA haplotype
15. Functions of hepatitis B surface proteins
16. An antibody which precipitates Dane particles in acute type B: relation to reception sites which bind polymerized human serum albumin on virus particles
17. Hepatitis virus preS gene encoded antigenic specificity and anti-preS antibody: relationship between anti-preS response and recovery
18. PreS1 antigens and antibodies early in the course of acute hepatitis B virus infection
19. The preS region of hepadnavirus envelope protein
20. Enhanced immunogenicity of the preS region of hepatitis B surface antigen
21. Immune response to the preS1 region of the hepatitis B surface antigen (HBsAg): a preS1 specific T cell response can bypass nonresponsiveness to the preS2 and S regions of HBsAg
22. Detection of antibodies to preS2 encoded epitopes of hepatitis B virus by monoclonal antibody-enzyme immunoassay
23. Synthesis in animal cells of hepatitis B surface antigen particles carrying a receptor for polymerized human serum albumin
24. Anti-preS2 antibodies in natural hepatitis B virus infection and after immunization
25. Immunochemical structure of the hepatitis B surface antigen vaccine. Treatment of immobilized HBsAg by dissociation agents with or without enzymatic digestion and identification of polypeptides by protein blotting
26. Immunochemical structure of the hepatitis B surface antigen vaccine. II. An analysis of antibody responses in human sera against the envelope proteins
27. Antibodies to a synthetic peptide from preS 120–145 region of the hepatitis B virus envelope are virus neutralizing
28. A synthetic peptide vaccine involving the product of the preS2 region of hepatitis B DNA: protective efficacy in chimpanzees
29. A biphasic pattern of anti-preS responses in acute hepatitis B virus infection
30. Randomized dose range study of a recombinant hepatitis B vaccine produced in mammalian cells and containing the S and preS2 sequences
31. Immunogenicity and safety in newborns of a new recombinant hepatitis B vaccine containing the S and preS2 antigens
32. Induction of protection level of anti-preS2 antibodies in humans immunized with a novel hepatitis B vaccine consisting of M (preS2+S) protein particles (a third generation vaccine)
33. Apparent discrepancies between immunochemical methods used for ovalbumin recognition in food
34. Two distinct but overlapping antibody binding sites in the preS2 region of HBsAg localized within 11 continuous residues
35. Interaction between hepatitis B surface proteins and monomeric human serum albumin
36. Properties of a recombinant yeast-derived hepatitis B surface antigen containing S, preS2 and preS1 antigenic domain
37. Recombinant versus plasma derived hepatitis B vaccine; comparison of immunogenicity in medical students
38. Long-term immunogenicity and efficacy of hepatitis B vaccine in homosexual men
39. Hepatitis B in a nonresponder to hepatitis B vaccine
40. Vaccine-induced escape mutant of hepatitis B virus
41. Independent emergence of a vaccine-induced escape mutant of hepatitis B virus
42. Gly 145 to arg substitution in HBs antigen of immune escape mutant of hepatitis B virus
43. Surface antigen and polymerase gene variation in hepatitis B virus isolates from a monoclonal antibody treated liver transplant patient